Gemini Therapeutics (NASDAQ:GMTX) Shares Up 0.7% - Time to Buy?

Key Points

• Gemini Therapeutics shares rose by 0.7%, reaching a last trading price of $70.75 after a significant increase in trading volume.
• The company focuses on developing precision medicine for age-related macular degeneration (AMD), with its lead candidate being GEM103.
• Gemini Therapeutics has a market capitalization of $3.07 billion and a P/E ratio of -70.75, indicating potential challenges in profitability.

Gemini Therapeutics, Inc. (NASDAQ:GMTX - )'s stock price was up 0.7% during mid-day trading on Friday . The company traded as high as $71.13 and last traded at $70.75. Approximately 509,349 shares were traded during trading, an increase of 169% from the average daily volume of 189,291 shares. The stock had previously closed at $70.28.

Gemini Therapeutics Stock Up 0.7%

The business has a fifty day moving average price of $61.65 and a 200-day moving average price of $53.70. The stock has a market capitalization of $3.07 billion, a P/E ratio of -70.75 and a beta of -0.12.

About Gemini Therapeutics

Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.